ASPIRA PATHLAB & DIAGNOSTICS | DHANVANTRI JEEV | ASPIRA PATHLAB & DIAGNOSTICS / DHANVANTRI JEEV |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.4 | 35.6 | - | View Chart |
P/BV | x | 2.6 | 0.9 | 277.8% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
ASPIRA PATHLAB & DIAGNOSTICS DHANVANTRI JEEV |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
DHANVANTRI JEEV Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / DHANVANTRI JEEV |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 18 | 419.0% | |
Low | Rs | 26 | 9 | 275.8% | |
Sales per share (Unadj.) | Rs | 14.0 | 43.1 | 32.6% | |
Earnings per share (Unadj.) | Rs | -0.1 | -0.5 | 16.3% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 1.8 | 80.7% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 12.4 | 22.7 | 54.6% | |
Shares outstanding (eoy) | m | 10.29 | 4.10 | 251.0% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 0.3 | 1,136.5% | |
Avg P/E ratio | x | -583.7 | -25.7 | 2,269.7% | |
P/CF ratio (eoy) | x | 34.6 | 7.5 | 458.6% | |
Price / Book Value ratio | x | 4.1 | 0.6 | 678.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 518 | 56 | 929.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 38 | 147.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 177 | 81.8% | |
Other income | Rs m | 3 | 2 | 134.9% | |
Total revenues | Rs m | 148 | 179 | 82.5% | |
Gross profit | Rs m | 16 | 6 | 274.7% | |
Depreciation | Rs m | 16 | 10 | 166.1% | |
Interest | Rs m | 4 | 0 | 5,957.1% | |
Profit before tax | Rs m | -1 | -1 | 61.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 1 | 0.0% | |
Profit after tax | Rs m | -1 | -2 | 41.0% | |
Gross profit margin | % | 11.0 | 3.3 | 335.9% | |
Effective tax rate | % | 0 | -50.2 | 0.0% | |
Net profit margin | % | -0.6 | -1.2 | 50.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 36 | 162.4% | |
Current liabilities | Rs m | 16 | 29 | 54.5% | |
Net working cap to sales | % | 29.5 | 3.9 | 750.1% | |
Current ratio | x | 3.7 | 1.2 | 298.1% | |
Inventory Days | Days | 88 | 34 | 254.7% | |
Debtors Days | Days | 590 | 50,580,391 | 0.0% | |
Net fixed assets | Rs m | 115 | 102 | 112.5% | |
Share capital | Rs m | 103 | 42 | 247.8% | |
"Free" reserves | Rs m | 25 | 52 | 47.7% | |
Net worth | Rs m | 128 | 93 | 137.0% | |
Long term debt | Rs m | 10 | 0 | - | |
Total assets | Rs m | 173 | 138 | 125.5% | |
Interest coverage | x | 0.8 | -19.6 | -4.0% | |
Debt to equity ratio | x | 0.1 | 0 | - | |
Sales to assets ratio | x | 0.8 | 1.3 | 65.1% | |
Return on assets | % | 1.9 | -1.5 | -124.8% | |
Return on equity | % | -0.7 | -2.3 | 29.9% | |
Return on capital | % | 2.4 | -1.5 | -162.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | -4 | 3.1% | |
From Investments | Rs m | 2 | -6 | -28.4% | |
From Financial Activity | Rs m | -9 | NA | - | |
Net Cashflow | Rs m | -8 | -10 | 82.9% |
Indian Promoters | % | 18.7 | 19.7 | 95.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 80.4 | 101.2% | |
Shareholders | 1,512 | 1,478 | 102.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE KIMS NARAYANA HRUDAYALAYA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | DHAN JEEVAN | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.14% | 0.00% | 0.45% |
1-Month | -8.93% | -15.10% | 2.55% |
1-Year | -3.33% | 43.37% | 56.14% |
3-Year CAGR | 1.86% | 45.44% | 15.22% |
5-Year CAGR | -1.91% | 9.09% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the DHAN JEEVAN share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of DHAN JEEVAN the stake stands at 19.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of DHAN JEEVAN.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
DHAN JEEVAN paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of DHAN JEEVAN.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.